Research prototype, not medical advice.

In the LoDoCo2 phase III trial, low-dose colchicine reduced cardiovascular events in chronic coronary disease; it was approved by the FDA in 2023 for cardiovascular prevention.

Confidence
Established
Level of evidence
Approved by a health authority
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Chronic inflammationLow-dose colchicineCardiovascular disease

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Colchicine in Patients with Chronic Coronary Disease
Nidorf et al. · New England Journal of Medicine 2020
— Verified

Related claims